In this interview, we speak to Jenn Edwards from the Abigail Wexner Research Institute (OH, USA) about her research using the primary human epithelial cell models to examine Neisseria gonorrhoeae infections, the potential for vaccination against gonorrhea and a possible host-targeted therapy for this infection.
In this infographic we give you a visual snapshot of the antibiotics introduced for gonorrhea and a timeline of when resistance was first identified, in addition to setting out some of the primary resistance mechanisms.
A report analyzing the prevalence and incidence of chlamydia, gonorrhea, trichomoniasis and syphilis for 2016 has reported that rates of these four curable sexually transmitted infections remain high, estimating 376.4 million cases in 2016.
New research has suggested that a combination treatment of gentamicin with azithromycin was almost as effective as the currently used ceftriaxone for treating genital gonorrhea.
A Phase II, muti-center, randomized, open-label trial has reported that a novel oral antibiotic, zoliflodacin, is effective in the treatment of uncomplicated urogenital gonorrhea.
The European Gonococcal Antimicrobial Surveillance Programme has revealed high levels of azithromycin resistance in Europe, however, these have remained relatively stable.
A new study has revealed gender-specific differences in infection and in antibiotic resistance genes during N. gonorrhoeae infection.
Data from Public Health England has reported a 20% rise in cases of syphilis and a 22% rise in gonorrhoea, a concern with the emergence of multi-drug resistance.
New research has identified growth-restoring mutations in ceftriaxone-resistant gonorrhoea strains, providing insight into this bacteria’s evolution and raising concerns over the spread of this ‘superbug’.